Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
6-K - Apollomics Inc. (0001944885) (Filer)
6-K - Apollomics Inc. (0001944885) (Filer)
6-K - Apollomics Inc. (0001944885) (Filer)
NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional information requested from the company. The last sale price of the company's ordinary shares was $18.4331 (NASDAQ:APLM), and warrants was $0.0191 (NASDAQ:APLMW). Trading will remain halted until Apollomics Inc. has fully satisfied Nasdaq's request for additional information. For news and additional information about the company, please contact the company directly or check under the company's symbol using InfoQuotesSM on the Nasdaq® Web site. For more information about The Nasdaq Stock
Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor ("EGFRi") to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib development program, including in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification$9.8 million in cash and cash equivalents as of December 31, 2024, in conjunction with LaunXP upfront payment, pipeline focus and expense reductions expected to provide cash runway into the first quarter of 2026 FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical bio
LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer ("NSCLC")Apollomics to receive upfront payments of $10 million, and is eligible for pre-commercial milestones up to $50 million, and royalties on net product sales FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics"), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, and LaunXP International Co.,
SC 13D/A - Apollomics Inc. (0001944885) (Subject)
SC 13G/A - Apollomics Inc. (0001944885) (Subject)
SC 13D/A - Apollomics Inc. (0001944885) (Subject)
Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-
FOSTER CITY, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. ("Apollomics" or the "Company"), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today announced that the Company will report full year 2023 financial results on Thursday, March 28, 2024, before the opening of the U.S. financial markets. Apollomics' management team will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The conference call will be available on Apollomics' website, www.apollomicsinc.com, under the Investors section and will be archived there for approximately 90 days. The co
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half 2023 Approximately $52.6 million in cash, cash equivalents, and investments at June 30, 2023; Cash runway to mid-year 2024 Debuted as a publicly traded targeted oncology company March 30, 2023 Management to host conference call Monday, October 2, 2023 at 8:30 a.m. ET FOSTER CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (NASDAQ:APLM) (the "Company"), a late- stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today annou